摘要
目的评价FOLFOX与XELOX方案治疗远处转移性结直肠癌的经济学效果。方法105例患者入组,其中FOLFOX方案组69例,接受每3周1个疗程的奥沙利铂+亚叶酸钙+5-氟尿嘧啶持续静脉注射的FOLFOX治疗方案;XELOX组36例,接受每3周1个疗程的奥沙利铂+卡培他滨治疗方案。评价2组的疗效及不良反应,并进行成本-效果分析。结果FOLFOX和XELOX组总有效率分别为58.0%和41.7%,总成本分别为15914.25和22239.26元;成本-效果比分别为274.39和533.31,因FOLFOX治疗方案成本低而效果高于XELOX方案,故无需进行增量成本分析。FOLFOX组胃肠道不良反应发生率明显高于XELOX组(78.3%vs.33.3%),差异有显著性(P<0.05)。结论FOLFOX方案治疗转移性结直肠癌的成本-效果优于XELOX方案。但其胃肠道不良反应发生率较高,同时持续注射给药给患者带来较多不便。
Objective To evaluate the cost - effectiveness outcome of FOLFOX regimen and XELOX regimen in the therapy of metastatic colorectal cancer. Methods A retrospective analysis was used to compare FOLFOX and XELOX regimen according to pharmacoeconomic costeffectiveness method. A total of 105 patients were enrolled： 69 received FOLFOX regimen and 36 received XELOX regimen. Results The C/E ratio of FOLFOX and XELOX group were 274. 39 and 533.31, respectively. And the incremental cost effectiveness ratio wash＇ t analyzed because of the high effectiveness and low cost of FOLFOX regimen. The ADRs including nausea and disgorging had significant difference between two groups （ P 〈0.05 ）. Conclusion The cost - effectiveness of the FOLFOX regimen was superior of two regimens, but the high ADRs ratio and continue intravenous administration would depress the patient compliance.
出处
《今日药学》
CAS
2009年第8期16-19,共4页
Pharmacy Today
